Oneiro Lifecare

What Oneiro Lifecare does

Oneiro Lifecare Pvt. Ltd. is an India-based pharmaceutical manufacturer founded in 2004 and headquartered in Vadodara, Gujarat. The company produces Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates in a B2B model, supplying global drug manufacturers rather than finished-dose products. Its portfolio spans 16 APIs across therapeutic categories including proton pump inhibitors (Omeprazole, Esomeprazole), antidiabetics (Sitagliptin, Linagliptin, Dapagliflozin, Empagliflozin, Vildagliptin), antitussives (Dextromethorphan HBr), antihistamines (Bilastine), anti-inflammatories (Celecoxib, Allopurinol), antiarrhythmics (Sacubitril Valsartan), antivirals (Molnupiravir), antiplatelets (Ticagrelor), and vitamins (Folic Acid), together with 10 categories of corresponding intermediates. Products are sold under quote-based, multi-year B2B contracts; no public pricing is disclosed.

Manufacturing is conducted at a 42,000 sq mtr facility in Padra, Vadodara, with four plants totaling 1,450 sq mtr and a full utility infrastructure (Boiler, Brine, Soft Water, RO, Chilled Water, Cooling Tower, DM Water, N2, Evaporator, Effluent Treatment Plant). The facility is WHO GMP-compliant and ISO 9001:2000 certified, serving as the principal regulatory moat for accessing regulated pharmaceutical markets. The company has built a commercial footprint across 35+ countries spanning North America, Latin America, Europe, Asia, the Middle East, and Africa, reaching customers through direct B2B sales relationships.

The company is privately held with no disclosed institutional investors, parent company, funding rounds, or M&A activity. Headcount is stated at 220 on the infrastructure page (with a firmographic range of 501-1,000). No AI/ML, digital platform, or public API capabilities are present; the technology stack is entirely conventional pharmaceutical manufacturing. Revenue is not publicly disclosed. Notable operational change in 2025 includes the retirement of SM Bakshi (GM-Operations since 2018). Marketing is primarily through the corporate website and educational blog content targeting pharmaceutical industry buyers.

Name

Oneiro Lifecare

Legal name

ONEIRO LIFECARE PVT. LTD.

Website

https://oneirolifecare.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Oneiro Lifecare is an India-based B2B manufacturer of Active Pharmaceutical Ingredients and pharmaceutical intermediates, operating a WHO GMP-compliant facility in Vadodara and exporting to pharmaceutical manufacturers in over 35 countries.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Active Pharmaceutical Ingredients
• Pharmaceutical Intermediates
• Bulk Drug Manufacturing
• API Contract Manufacturing
• GMP Pharmaceutical Manufacturing

Headquarters

HQ city

Vadodara

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. API Sales: Direct sale of Active Pharmaceutical Ingredients including Dextromethorphan HBr, Omeprazole, Esomeprazole Mg. Trihydrate, Folic Acid, Pregabalin, and other specialty APIs to pharmaceutical manufacturers
2. Pharmaceutical Intermediates: Manufacturing and sale of pharmaceutical intermediates used as raw materials in drug manufacturing, including intermediates for Omeprazole, Clopidogrel, Dextromethorphan HBr, Carvedilol, Lamotrigine, and Quinoline Phosphate

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Oneiro Lifecare manufactures and supplies Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates used as raw materials in drug production. Operating from a WHO GMP-compliant, ISO 9001:2000 certified manufacturing facility in Vadodara, India, the company produces a portfolio spanning 16 APIs across therapeutic classes such as gastrointestinal, antidiabetic, antihistamine, antitussive, anti-inflammatory, antiarrhythmic, antiviral, antiplatelet, and vitamin categories, alongside multiple pharmaceutical intermediates. The company sells these bulk pharmaceutical ingredients directly to global drug manufacturers across more than 35 countries.

Product overview

Oneiro Lifecare is a pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. The company operates as a single-product portfolio manufacturer offering 16 distinct APIs across therapeutic categories (antigastro, antidiabetic, antihistamine, antitussives, anti-inflammatory, antiarrhythmic, antiviral, vitamin complex, antiplatelet, and anti-hyperglycemic) along with 10 categories of pharmaceutical intermediates. The product portfolio includes core APIs such as Omeprazole, Esomeprazole, Dextromethorphan HBr, Sitagliptin, Vildagliptin, Folic Acid, and Pregabalin, alongside specialized intermediates for manufacturing these and other drugs. The company's manufacturing infrastructure is WHO GMP-compliant and ISO 9001:2000 certified, serving pharmaceutical companies in over 35 countries as a B2B raw material supplier.

Differentiator

Problem solved

Functional benefit

Products and services

• Omeprazole A proton pump inhibitor API used for treating acid-related conditions such as GERD, peptic ulcers, and Zollinger-Ellison syndrome.
• Esomeprazole The S-isomer of omeprazole, a proton pump inhibitor API used for treating gastroesophageal reflux disease (GERD) and related acid conditions.
• Sitagliptin Phosphate Monohydrate A DPP-4 inhibitor API used for managing type 2 diabetes by enhancing the body's ability to regulate insulin and blood glucose levels.
• Linagliptin A DPP-4 inhibitor API used for type 2 diabetes treatment, working by increasing incretin hormones that stimulate insulin release.
• Dapagliflozin Propanediol Monohydrate An SGLT2 inhibitor API used to treat type 2 diabetes by helping the kidneys remove glucose from the body through urine.
• Empagliflozin An SGLT2 inhibitor API used for type 2 diabetes management, also showing cardiovascular and renal benefits.
• Bilastine A second-generation antihistamine API used for treating allergic rhinitis and urticaria with non-sedating properties.
• Dextromethorphan Hydrobromide An antitussive API used for suppressing coughs in both pediatric and adult formulations.
• Celecoxib A COX-2 selective NSAID API used for treating osteoarthritis, rheumatoid arthritis, and acute pain.
• Allopurinol An anti-inflammatory API used primarily for treating gout and hyperuricemia by inhibiting xanthine oxidase.
• Sacubitril Valsartan Sodium Salt An antiarrhythmic API used for treating heart failure, combining neprilysin inhibition with angiotensin receptor blockade.
• Sacubitril Valsartan Trisodium Hemi Pentahydrate A specific hydrate form of the sacubitril valsartan complex API used in heart failure treatment.
• Molnupiravir An antiviral API used for treating mild-to-moderate COVID-19 in adults at high risk of disease progression.
• Folic Acid A vitamin complex API essential for DNA synthesis, cell division, and treating folate deficiency anemia.
• Ticagrelor An antiplatelet API used with aspirin for preventing thrombotic events in patients with acute coronary syndrome.
• Vildagliptin An anti-hyperglycemic API (DPP-4 inhibitor) used for type 2 diabetes management, either alone or in combination with metformin.
• Intermediates for Omeprazole/Esomeprazole Key intermediates including 2-Chloromethyl-3,5-Dimethyl-4-methoxypyridine hydrochloride and related compounds used in the synthesis of Omeprazole and Esomeprazole APIs.
• Intermediates for Dextromethorphan HBr Specialized intermediates including 3-Methoxy Morphinan, N-Formyl 3-Methoxy Morphinan, and Dextromethorphan Base used in Dextromethorphan Hydrobromide synthesis.
• Intermediates for Clopidogrel Cyclic Amine intermediate used in the synthesis of Clopidogrel Bisulfate API for antiplatelet applications.
• Intermediates for Carvedilol 1,2,3,9-Tetrahydro carbazole-4-one intermediate used in the synthesis of Carvedilol API for anti-hypertension treatment.
• Intermediates for Lamotrigine 2,3-Dichloro Benzoyl Nitrile intermediate used in the synthesis of Lamotrigine API for anticonvulsant applications.
• Intermediates for Hydroxychloroquine Antimalarial intermediates including Hydroxynovaldiamine and 4,7-Dichloroquinoline used in Hydroxychloroquine synthesis.
• Intermediates for Losartan 2-N-Butyl-4-Chloro-5-Formyl Imidazole intermediate used in the synthesis of Losartan API for hypertension treatment.
• Intermediates for Vildagliptin 3-Amino-1-Adamantanol intermediate used in the synthesis of Vildagliptin API for anti-hyperglycemic applications.
• Intermediates for Anti-inflammatory drugs 4-Sulfonamido Phenyl Hydrazine Hydrochloride intermediate used in the synthesis of anti-inflammatory APIs.

Quantifiable outcome

• Serving pharmaceutical manufacturers in 35+ countries

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Granules India: Indian API and pharmaceutical intermediates manufacturer with a multi-therapeutic portfolio and global customer base. Directly comparable on product type (APIs/intermediates), Indian manufacturing base, and B2B go-to-market.
• Ipca Laboratories: Indian API manufacturer with strong presence in generics and intermediates, exporting globally. Comparable therapeutic-area breadth and customer profile to Oneiro.
• Jubilant Pharmova: Indian pharma company with API, CDMO, and generics businesses. Comparable in manufacturing APIs and intermediates for global customers across multiple therapeutic areas.
• Divis Laboratories: Large Indian API and intermediates manufacturer serving global generic and innovator pharma. Operates in the same product category as Oneiro with a far larger scale; useful as a scaled-up comparable.
• Laurus Labs: Indian-headquartered API and intermediates manufacturer supplying global generics companies. Closely comparable to Oneiro in product mix (APIs + intermediates), B2B export model, and focus on regulated markets.

Broad incumbents

• Cadila Healthcare (Zydus): Diversified Indian pharma group with API manufacturing, formulations, and biosimilars. Competes with Oneiro in API/intermediate supply but serves a much larger finished-product portfolio.
• Dr. Reddy's Laboratories: Major Indian pharmaceutical company with a significant API business alongside branded generics and biosimilars. Comparable API/intermediates manufacturing capabilities but operates across a much broader product set.
• Aurobindo Pharma: Vertically integrated Indian generic pharma with substantial API manufacturing operations. Overlaps with Oneiro on API/intermediates supply but operates across finished dosage forms, biosimilars, and a much wider portfolio.
• Sun Pharmaceutical Industries: India's largest pharma company with in-house API manufacturing for its generics portfolio. Significant overlap with Oneiro's product categories at much greater scale and broader geographic reach.

Emerging players

• Sequent Scientific: Indian API manufacturer focused on veterinary and select human health APIs. Comparable mid-sized Indian API manufacturer serving global B2B customers, though narrower in therapeutic scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/oneirochem

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oneiro Lifecare